Cephalon Can't Rely on Patent in Reverse-Payment Antitrust Case

Cephalon can't rely on the strength of its patent for a narcolepsy drug in a reverse-payment antitrust suit brought by the Federal Trade Commission because the judge found in a related case that the patent is invalid.

Online Only

All Columns

read more

Courts and Cases

read more

From the Blogs

read more

Special Reports

  • Litigation Departments of the Year

    The Litigation Departments of the Year supplement includes articles spotlighting the work of Pennsylvania's top litigation departments in a variety of practice areas.

  • Energy & Environmental Law

    The future of Philadelphia's oil industry; managing an environmental enforcement investigation; the next decade of PA shale development; the benefits of going green with alternative energy; and more can be found in our Energy and Environmental Law Supplement.

read more

Twitter Feed

Pa. Law Weekly

read more